This post is a follow-up to my earlier analysis of Radnostix’s business, the DUF6 asset sale, and the company’s position as America’s only domestic I-131 manufacturer.
The DUF6 Sale Is Dead
On March 16, 2026, Radnostix (OTCQB: INIS) disclosed the mutual termination, effective March 11th, of the Asset Purchase Agreement with American Fuel Resources for the company’s DUF6 plant and related assets.
The deal had been in progress since February 2024. AFR made $170,000 in non-refundable payments over that period: a $50,000 prepayment and twelve $10,000 NRC extension fees. The remaining $12.45 million was due at closing. AFR contacted Radnostix requesting a one-year extension because it could not make payment by the March 31, 2026 outside date. The parties were in the final stages of the NRC consent process to transfer the license, but mutually agreed to withdraw the application and terminate the agreement.
In the original analysis, I laid out what happens if this deal fails:
Company continues with ~$1.65M cash and roughly breakeven operations. Liens remain on core assets, limiting future financing flexibility. Series C preferred becomes a more pressing concern as February 2027 approaches. Any significant supply disruption could require additional equity financing.
That is now the situation. The balance sheet transformation the original thesis depended on will not happen. The $10.2 million in net cash, the lien removal from the I-131 ANDA and Hot Cell facility, the ability to retire the $4.06 million Series C preferred stock from cash, the operational cushion to absorb supply disruptions: all of it required this transaction to close.
Management’s 8-K states they “decided it was in the best interest of the shareholders to regain control of the assets as we believe they have appreciated in value since entering the APA” and that they had “low confidence that AFR would be able to secure funding to close the deal by the requested extension date.” The company says it will evaluate all options for the DUF6 plant going forward.
The optimistic read is that uranium market dynamics have improved and the assets could sell for more than $12.5 million to a different buyer. That is possible. But AFR spent two years in the process, went through NRC review, and made non-refundable payments, and still could not come up with the funding. A new sale process would mean finding a new buyer, negotiating new terms, and restarting the NRC consent process from scratch. None of that has a timeline attached to it.
A Recall on the Core Business
The same 8-K disclosed a second issue. On February 19, 2026, the company discovered during an internal audit that specific lots of its Dibasic Sodium Phosphate Capsules shipped between August 2024 and February 2026 may be out of specification due to final capsule weight. These capsules are provided alongside the company’s Generic Sodium Iodide I-131 kits. The company initiated a voluntary recall with FDA knowledge.
The Generic Sodium Iodide I-131 product itself was not affected, and the company says it does not expect the recall to materially impact its ability to serve practitioners or their patients.
One-time charges:
| Item | Amount | Period |
|---|---|---|
| Inventory write-off | ~$75,000 | Q4 2025 |
| Customer refunds | ~$50,000 | Q1 2026 |
| Replacement capsule inventory | ~$75,000 | Q1 2026 |
Ongoing impact:
| Item | Amount | Period |
|---|---|---|
| Lost revenue per week | $25,000 to $75,000 | Through Q2 2026 |
The company states Q1 was not materially impacted beyond the refunds listed above, so the weekly revenue loss appears limited to Q2. Over a 13-week quarter, that translates to $325,000 to $975,000 in lost revenue. For a $14 million revenue company, that is a meaningful headwind but not an existential one.
The Financial Picture
Without the DUF6 proceeds, the company’s near-term financial situation is straightforward:
| Metric | Status |
|---|---|
| Available cash | ~$1.65M |
| Series C preferred due | $4.06M, February 2027 |
| Liens on ANDA and Hot Cell | Still in place |
| Insider notes outstanding | $1.62M + accrued interest |
| Going concern language | References future equity financing |
The Series C preferred is now less than eleven months from maturity. The insider holders (John McCormack’s family trusts and Chairman Christopher Grosso) have extended this obligation three times before. They may do so again. But each extension reflects a company that cannot generate enough cash to meet its obligations on schedule.
The going concern language in the most recent 10-Q states the company expects “cash from operations, cash raised via equity financing, and our current cash balance will be sufficient to fund operations for the next twelve months.” With 528 million shares already outstanding and the stock at $0.06, any equity raise involves significant dilution.
The Core Business Still Exists
None of this changes the fundamental value of what Radnostix does. The company still manufactures the only US-produced FDA-approved generic Iodine-131 product. The theranostics market is still growing. The second I-131 supplier that came online in mid-2025 reduces the supply chain risk that hurt 2025 results. RadQual’s calibration business grew 57% in the first nine months of 2025.
The question was never whether Radnostix has a real business. The question was whether the DUF6 sale would provide the financial foundation to let that business compound without the constant overhang of tight cash, insider debt, and preferred stock maturities. The answer turned out to be no.
A patient investor could argue the core I-131 business eventually generates enough cash to resolve these issues organically. Revenue has grown from $10.6 million in 2022 to a $13-14 million run rate, and with two suppliers now active, 2026 should benefit from fewer disruptions. But “eventually” is doing a lot of work when a $4.06 million preferred stock maturity sits eleven months away and available cash is $1.65 million.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Q4 2025 earnings | First full disclosure of recall impact and post-DUF6 financial plan | March/April 2026 |
| Recall resolution | Weekly revenue loss of $25K-$75K persists until resolved; company expects impact contained to Q2 | Q2 2026 |
| Series C preferred resolution | Extension, conversion, or redemption of $4.06M obligation | By February 2027 |
| DUF6 remarketing | Any announcement of a new buyer or sale process | No process announced |
| EasyFill launch | Medical Devices commercialization could provide incremental revenue | Originally Q3 2026 |
Sources:
- 8-K filed March 16, 2026 (DUF6 termination and product recall)
- 10-Q for quarter ending September 30, 2025
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.